Treatment of Experimental Brain Tumors with Trombospondin-1 Derived Peptides: An in Vivo Imaging Study

Neoplasia

Volumn 1, Issue 5, 1999, Pages 438-445

  Bogdanov Jr , A ^a   Marecos, E ^a   Cheng, H C ^b   Chandrasekaran, L ^c   Krutzsch, H C ^c   Roberts, D D ^c   Weissleder, R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Veterans Hospital   (Taiwan)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Anti angiogenesis; Imaging; Magnetic resonance; Peptide; Thrombospondin 1

Indexed keywords

PEPTIDE; THROMBOSPONDIN 1;

ANIMAL; ARTICLE; BRAIN TUMOR; CANCER TRANSPLANTATION; CELL CULTURE; DOSE RESPONSE; ELECTRON SPIN RESONANCE; FEMALE; FISCHER 344 RAT; FLUORESCENCE MICROSCOPY; GLIOMA; GLIOSARCOMA; IMMUNOHISTOCHEMISTRY; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; RAT; TISSUE DISTRIBUTION; VASCULARIZATION;

ANIMALS; BRAIN NEOPLASMS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTRON SPIN RESONANCE SPECTROSCOPY; FEMALE; GLIOMA; GLIOSARCOMA; IMMUNOHISTOCHEMISTRY; MAGNETIC RESONANCE IMAGING; MICROSCOPY, FLUORESCENCE; NEOPLASM TRANSPLANTATION; PEPTIDES; RATS; RATS, INBRED F344; THROMBOSPONDIN 1; TISSUE DISTRIBUTION; TUMOR CELLS, CULTURED;

EID: 0033222264     PISSN: 15228002     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.neo.7900044     Document Type: Article

References (47)

1. Guo N, Krutzsch H, Inman J, and Roberts D (1997). Thrombospondin 1 and type I repeat peptides of thrombospondin 1 specifically induce apoptosis of endothelial cells. Cancer Res 57, 1735-1742.
2. Guo H, Krutzsch H, Inman J, Shannon C, and Roberts D (1997). Anti-proliferative and anti-tumor activities of D-reverse peptides from the second type-1 repeat of thrombospondin-1. J Peptide Res 50, 210-217.
3. Folkman J (1995). Angiogenesis in cancer, vascular, rheumatoid and other disease. Nature Med 1, 27-31.
4. Folkman J (1997). Angiogenesis and angiogenesis inhibition: an overview. EXS 79, 1-8.
5. Hanahan D, and Folkman J (1996). Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86, 353-364.
6. Weidner N, Folkman J, Pozza F, Bevilacqua P, Allred E, Moore D, Meli S, and Gasparini G (1992). Tumor angiogenesis: a new significant and independent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst 84, 1875-1887.
7. Abdulrauf S, Edvardsen K, Ho K, Yang X, Rock J, and Rosenblum M (1998). Vascular endothelial growth factor expression and vascular density as prognostic markers of survival in patients with low-grade astrocytoma. J Neurosurgery 88, 513-520.
8. O'Reilly MS, Holmgren L, Chen C, and Folkman J (1996). Angiostatin induces and sustains dormancy of human primary tumors in mice. Nature Med 2, 689-692.
9. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, and Folkman J (1997). Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 88, 277-285.
10. Blumenthal RD, Sharkey RM, Haywood L, Natale AM, Wong GY, Siegel JA, Kennel SJ, and Goldenberg DM (1992). Targeted therapy of athymic mice bearing GW-39 human colonic cancer micrometastases with 1311-labeled monoclonal antibodies. Cancer Res 52, 6036-6044.
11. Molema G, Meijer DK, and de Leij LF (1998). Tumor vasculature targeted therapies: getting the players organized. Biochem Pharmacol 55, 1939-1945.
12. Dachs GU, Dougherty GJ, Stratford IJ, and Chaplin DJ (1997). Targeting gene therapy to cancer: a review. Oncol Res 9, 313-325.
13. Saleh M, Stacker SA, and Wilks AF (1996). Inhibition of growth of C6 glioma cells in vivo by expression of antisense vascular endothelial growth factor sequence. Cancer Res 56, 393-401.
14. Oku T, Tjuvajev JG, Miyagawa T, Sasajima T, Joshi A, Joshi R, Finn R, Claffey KP, and Blasberg RG (1998). Tumor growth modulation by sense and antisense vascular endothelial growth factor gene expression: effects on angiogenesis, vascular permeability, blood volume, blood flow, fluorodeoxyglucose uptake, and proliferation of human melanoma intracerebral xenografts. Cancer Res 58, 4185-4192.
15. Im SA, Gomez-Manzano C, Fueyo J, Liu TJ, Ke LD, Kim JS, Lee HY, Steck PA, Kyritsis AP, and Yung WK (1999). Antiangiogenesis treatment for gliomas: transfer of antisense-vascular endothelial growth factor inhibits tumor growth in vivo. Cancer Res 59, 895-900.
16. Kirsch M, Strasser J, Allende R, Bello L, Zhang J, and Black PM (1998). Angiostatin suppresses malignant glioma growth in vivo. Cancer Res 58, 4654-4659.
17. Griscelli F, Li H, Bennaceur-Griscelli A, Soria J, Opolon P, Soria C, Perricaudet M, Yeh P, and Lu H (1998). Angiostatin gene transfer: inhibition of tumor growth in vivo by blockage of endothelial cell proliferation associated with a mitosis arrest. Proc Natl Acad Sci USA 95, 6367-6372.
18. Tanaka T, Cao Y, Folkman J, and Fine HA (1998). Viral vector-targeted antiangiogenic gene therapy utilizing an angiostatin complementary DNA. Cancer Res 58, 3362-3369.
19. Good D, Polverini P, Rastinejad F, Le Beau M, Lemosn R, Frazier W, and Bouck N (1990). A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci USA 87, 6624-6628.
20. Taraboletti G, Roberts D, Liotta LA, and Giavazzi R (1990). Platelet thrombospondin modulates endothelial cell adhesion, motility, and growth: a potential angiogenesis regulatory factor. J Cell Biol 111, 765-772.
21. Murphy Ullrich J, and M H (1989). Thrombospondin modulates focal adhesions in endothelial cells. J Cell Biol 109, 1309-1319.
22. Vogel T, Guo N, Krutzsch H, Blake D, Hartman J, Mendelovitz S, Panet A, and Roberts D (1993). Modulation of endothelial cell proliferation, adhesion, and motility by recombinant heparin-binding domain and synthetic peptides from the type I repeats of thrombospondin. J Cell Biochem 53, 74-84.
23. Weinstat-Saslow D, Zabrenetzky V, VanHoutte K, Frazier W, Roberts D, and Steeg P (1994). Transfection of thrombospondin 1 complementary DNA into a human breast carcinoma cell line reduces primary tumor growth, metastatic potential, and angiogenesis. Cancer Res 54, 6504-6511.
24. Dameron KM, Volpert OV, Tainsky MA, and Bouck N (1994). Control of angiogenesis in fibroblasts by p53 regulation of thrombospondin-1. Science 265, 1582-1584.
25. Hsu SC, Volpert OV, Steck PA, Mikkelsen T, Polverini PJ, Rao S, Chou P, and Bouck NP (1996). Inhibition of angiogenesis in human glioblastomas by chromosome 10 induction of thrombospondin-1. Cancer Res 56, 5684-5691.
26. Sheibani N, and Frazier W (1995). Thrombospondin 1 expression in transformed endothelial cells restores a normal phenotype and suppresses their tumorigenesis. Proc Natl Acad Sci USA 92, 6788-6792.
27. Tolsma S, Volpert O, Good D, Frazier W, Polverini P, and Bouck N (1993). Peptides derived from two separate domains of the matrix protein thrombospondin-1 have antiangiogenic properties. J Cell Biol 122, 497-511.
28. Moore A, Marecos E, Simonova M, Weissleder R, and Bogdanov A, Jr. (1998). Novel gliosarcoma cell line expressing green fluorescent protein: a model for quantitative assessment of angiogenesis. Microvasc Res 56, 145-153.
29. Bogdanov A, Jr., Wright SC, Marecos EM, Bogdanova AV, Martin C, Petherick P, and Weissleder R (1997). A long-circulating co-polymer in "passive targeting" to solid tumors. J Drug Targeting 4, 321-330.
30. Bogdanov A, Jr., Weissleder R, Tsai E, Schaffer B, Bogdanova A, Nossiff N, Papisov M, and Brady T (1993) Tumor neovascularity imaging by contrast-enhanced MR angiography. 12th Annual Scientific Meeting Of Society of Magnetic Resonance in Medicine, New York, NY. p. 577.
31. Bogdanov A, Jr., Weissleder R, Frank HW, Bogdanova AV, Nossif N, Schaffer BK, Tsai E, Papisov MI, and Brady TJ (1993). A new macromolecule as a contrast agent for MR angiography: preparation, properties, and animal studies. Radiology 187, 701-706.
32. Weissleder R, Cheng H, Marecos E, Kwon K, and Bogdanov A (1998). Mapping of tumor vascular and interstitial volume fractions non invasively in vivo. Eur J Cancer 34, 1444-1454.
33. Hendrick RE, and Haacke EM (1993). Basic physics of MR contrast agents and maximization of image contrast. JMRI 3, 137-148.
34. Donahue KM, Weisskoff RM, Chesler D, Kwong K, Bogdanov AA, Mandeville JB, and Rosen BR (1996). Improving MR quantification of regional blood volume with intravascular T1 contrast agents: accuracy, precision, and water exchange. Magn Reson Med 36, 858-867.
35. Smith K, Hill S, Begg A, and Denekamp J (1988). Validation of the fluorescent dye Hoechst 33342 as a vascular space marker in tumors. Br J Cancer 57, 247-253.
36. Vogel A (1965). Intratumoral vascular changes with increased size of a mammary adenocarcinoma: new method and results. J Natl Cancer Inst 34, 571-578.
37. Fallowfield M (1989). Vascular volume in B16 allografts and human melanoma xenografts estimated by means of Hoechst 33342. J Pathol 157, 249-252.
38. Samoto K, Ikezaki K, Ono M, Shono T, Kohno K, and Kuwano M (1995). Expression of vascular endothelial growth factor and its possible relation with neovascularization in human brain tumors. Cancer Res 55, 1189-1193.
39. Hansen S, Grabau D, Bak M, Rose C, and Sorensen F (1998). Estimating intratumoral microvessel density by different methods to determine angiogenesis in breast cancer: intra-and interobserver variability. Proceedings of AACR Symposium: Angiogenesis and Cancer, Orlando, FL. A-47.
40. Parangi S, O'Reilly M, Christofori G, Holmgren L, Grosfeld J, Folkman J, and Hanahan D (1996). Antiangiogenic therapy of transgenic mice impairs de novo tumor growth. Proc Natl Acad Sci USA 93, 2002-2007.
41. Boehm T, Folkman J, Browder T, and O'Reilly MS (1997). Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407.
42. Roberts DD (1996). Regulation of tumor growth and metastasis by thrombospondin-1. [69 refs]. FASEB J 10, 1183-1191.
43. Tuszynski GP, and Nicosia RF (1996). The role of thrombospondin-1 in tumor progression and angiogenesis. Bioessays 18, 71-76.
44. Qian X, and Tuszynski GP (1996). Expression of thrombospondin-1 in cancer: a role in tumor progression. Proc Soc Exp Biol Med 212, 199-207.
45. Dawson D, Volpert O, Pearce F, Schneider A, Silverstein R, Henkin J, and Bouck N (1999). Three distinct D-amino acid substitutions confer potent antiangiogenic activity on an inactive peptide derived from a thrombospondin type 1 peptide. Mol Pharmacol 55, 332-338.
46. Dennie J, Mandeville J, Boxerman J, Packard S, Rosen B, and Weisskoff R (1998). NMR imaging of changes in vascular morphology due to tumor angiogenesis. Magn Reson Med 40, 793-799.
47. Bergers G, Javaherian K, Lo K, Folkman J, and Hanahan D (1999). Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812.